SAN DIEGO, Aug 12, 2011 /PRNewswire/ — Arena Pharmaceuticals,
Inc. (NASDAQ:
ARNA) today announced that Robert E. Hoffman will rejoin Arena
on August 29, 2011, as Vice President, Finance and Chief Financial
Officer. Mr. Hoffman served in various financial positions with
Arena for over 13 years before departing in March to work for a
private biopharmaceutical company.
“Robert is a valuable leader who has been a key contributor to
Arena,” said Jack Lief, Arena’s President and Chief Executive
Officer. “Robert’s return comes at an important time for Arena as
we prepare to respond to the lorcaserin complete response
letter.”
Mr. Hoffman, 45, currently serves as a member of the Financial
Accounting Standards Board’s small business advisory committee and
the steering committee of the Association of Bioscience Financial
Officers. He is also a member and a former director and President
of the San Diego Chapter of Financial Executives International.
“I look forward to again working closely with my colleagues to
support Arena’s efforts to seek FDA approval of lorcaserin and to
advance select earlier-stage research and development programs,”
said Mr. Hoffman.
Mr. Hoffman previously served as Arena’s Vice President, Finance
and Chief Financial Officer from December 2005 to March 2011; Vice
President, Finance and Chief Accounting Officer from June 2004 to
December 2005; Vice President, Finance from April 2000 to June
2004; and Controller from August 1997 to April 2000.
About Arena PharmaceuticalsArena is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing oral drugs that target G protein-coupled receptors,
an important class of validated drug targets, in four major
therapeutic areas: cardiovascular, central nervous system,
inflammatory and metabolic diseases. Arena’s most advanced drug
candidate is intended for w
‘/>”/>
SOURCE
